The Antidote: Inside the World of New Pharma (67 page)

(
pp. 94
–96) Interviews with Ann Kwong and Josh Boger.

(
pp. 96
–99) Interviews with Geoffrey Porges and Josh Boger.
HBS
case studies;
Time
cover story, “Medicine: What the Doctor Ordered,” August 18, 1952; Jim Collins and Jerry Porras,
Built to Last,
HarperBusiness, 1994; “Vertex Slips 37% After Arthritis Test Halted,”
Boston Business Journal
, November 11, 2003; Geoffrey Porges, “Vertex Pharmaceuticals: Still Floundering,”
Bernstein Research Call
, October 17, 2003.

(
pp. 99
–102) Interviews with John Alam, Josh Boger, and Geoff Porges. Charles Pierce, “Boston’s Biotech Moment,”
Boston Globe Magazine
, December 14, 2003; David Hamilton, “The FDA’s Approval of Drugs Doesn’t Ensure Biotech Riches,”
Wall Street Journal
, October 29, 2003; Geoff Porges and Marshall Gordon, “VRTX: Investor Day Yields More Positives Than Negatives; Uncertainty Remains, Upgrade to Marketperform,”
Bernstein Research Call
, December 4, 2003.

(
pp. 105
–9) Interviews with Ian Smith, Josh Boger, Ken Boger, John Alam, and Ann Kwong. David Margolis, “11th Annual Retrovirus Conference,”
Conference Reports for NATAP
(National Aids Treatment Advocacy Project), February 8–11, 2004; Ann Kwong, Robert Kauffman, Patricia Hurter, and Peter Mueller, “Discovery and Development of Telaprevir,”
Nature Biotechnology
, November 2011.

(
pp. 109
–11) Interviews with Peter Mueller, Mark Murcko, Josh Boger, John Alam, and Vicki Sato.

(
pp. 111
–14) Interviews with Ian Smith, Vicki Sato, Trish Hurter, and Pat Connelly.

(
pp. 114
–17) Interviews with Josh Boger, Bink Garrison, and Vicki Sato. Gardiner Harris, “Drug Makers Seek to Mend Their Fractured Image,”
New York Times
, July 8, 2004; Jim Collins and Jerry Porras,
Built to Last
, HarperBusiness, 1994.

(
pp. 117
–21) Interviews with Vicki Sato, Roger Tung, Paul Negulescu, Eric Olson, Peter Grootenhuis, Fred Van Goor, and Sabine Hadida. Jerome Groopman, “Open Channels,”
New Yorker
, May 4, 2009 (Groopman was a member of Vertex’s original scientific advisory board); Penni Crabtree, “Poised to Be a Star: Cystic Fibrosis Project Has San Diego Unit of Vertex on Verge of Treatment,”
San Diego Union Tribune
, October 21, 2005; Matthew Herper, “A Drug of Your Own,”
Forbes
, July 20, 2011.

(
pp. 121
–24) Interviews with Josh Boger, Bink Garrison, Matt Emmens, and Trish Hurter. Anna Wilde Matthews and Barbara Martinez, “E-Mails Suggest Merck Knew Vioxx’s Dangers at Early Stage,”
Wall Street Journal
, November 1, 2004; Alex Berenson, Gardiner Harris, Barry Meier, and Andrew Pollack, “Despite Warnings, Drug Giant Took Long Path to Vioxx Recall,”
New York Times
, November 14, 2004.

(
pp. 125
–28) Interviews with Tim Neuberger, Paul Negulescu, and Vicki Sato.

(
pp. 128
–32) Interviews with Robert Kauffman, John Alam, Josh Boger, and Ian Smith. Scott Gottlieb, “Magic Bullet for Hepatitis C,”
Forbes
, January 24, 2005; Geoff Porges and Neil Agran, “VRTX: VX-950—‘Billion Dollar Molecule’ in New SCB Market Model,”
Bernstein Research Call
, June 8, 2005.

(
pp. 132
–35) Interviews with Trish Hurter, Bink Garrison, and Josh Boger.